SCHEMBL1900876

SCHEMBL1900876

Cc1[c]cnn1-c1cccnc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.45
CYP2E1 P05181 2/20 0.45
CYP3A4 P08684 2/20 0.45
ELANE P08246 1/20 0.44
HTT P42858 1/20 0.41
CYP11B2 P19099 1/20 0.41
GRM1 Q13255 4/20 0.40
AR P10275 1/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
ALOX12 P18054 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NFE2L2 Q16236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316519 0.80 RAB9A (0.41) HTTALDH1A1MAPT
SCHEMBL16927609 0.76 CYP11B2 (0.41) CYP2A6CYP2E1CYP3A4HTTCYP11B2
SCHEMBL1305113 0.76 CYP11B2 (0.41) CYP2A6CYP2E1CYP3A4HTTCYP11B2
SCHEMBL1908255 0.74 NPC1 (0.49) CYP3A4HTTIDO1TDO2ALDH1A1
SCHEMBL2691172 0.73 CYP2A6 (0.49) CYP2A6CYP2E1CYP3A4ELANEHTT
SCHEMBL4909016 0.72 RAB9A (0.43) CYP3A4ELANEHTTALDH1A1MAPT
SCHEMBL1902318 0.71 NPC1 (0.46) HTTGRM1IDO1TDO2ALDH1A1
SCHEMBL28335461 0.70 CYP2A6 (0.54) CYP2A6CYP2E1CYP3A4ELANEHTT
SCHEMBL1906114 0.70 CYP1A2 (0.47) HTTALDH1A1MAPTHSD17B10
SCHEMBL14955293 0.69 CA12 (0.51) CYP2A6CYP2E1CYP3A4ELANEHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 CYP2A6 3267/4885CYP2E1 4681/4885CYP3A4 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.